ArticleBiotechnology and applied biochemistry2026
Transient Transfection of Rolling-Circle Amplified DNA in Biomanufacturing-Relevant Mammalian Cell Lines: A Comparison of Transfection Conditions for Optimal Protein Expression.
Article in Biotechnology and applied biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel enzymatic DNA produced from a text file achieves comparable immune responses as plasmid vaccine.NPJ vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Rolling-circle amplification (RCA) is a completely synthetic and rapid mechanism for scaling-up bulk DNA that eliminates requirements for large-scale bacterial fermentation. Several reports have described the surprising ability of large unprocessed (hyperbranched) rolling circle-amplified DNA (RCA DNA) to effectively transfect cultured cells; however, to our knowledge a comprehensive analysis of transfection conditions has not been conducted for this unique type of large synthetic DNA. Herein, we present comparative transfection data for two of the most common mammalian cell types used in biopharmaceutical manufacturing (suspension Chinese hamster ovary CHO cells and adherent HEK293 cells) and a panel of commercial transfection reagents that represent three general compositions (i.e., cationic lipid, cationic polymer, and complex blends). We show the efficiency of RCA DNA delivery is highly influenced by the transfection reagent and cell line, but expression patterns generally track with plasmid controls. Reagents comprising complex blends provide some of the best transfection results for RCA DNA, although additional reagent types work well. We also show it is possible to transfect two different RCA DNA products into CHO cells to produce monoclonal antibodies at high titer. We conclude that large and unique synthetic DNA produced by RCA is capable of being used in place of supercoiled plasmid for downstream transfection workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.